Hyperglycemia and diabetes occurs with initiation of SIGNIFOR therapy; intensive glucose monitoring is recommended and may require initiation or adjustment of anti-diabetic treatment per standard...
Read real-world case studies and learn more about SIGNIFOR® (pasireotide) Injection for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
These case studies are examples only, and are not representative of all patients diagnosed with Cushing’s disease.
Patient Case Study: Lisa P.
Patient Case Study: Matthew S.
SIGNIFOR® (pasireotide) Injection, for subcutaneous use
SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions:
The most common adverse reactions (frequency ≥20% in either group) occurring in patients receiving SIGNIFOR in clinical trials were:
Please see full Prescribing Information.